126 filings
8-K
BEAM
Beam Therapeutics Inc
10 Jun 24
Submission of Matters to a Vote of Security Holders
4:30pm
10-Q
2024 Q1
BEAM
Beam Therapeutics Inc
Quarterly report
7 May 24
7:19am
8-K
BEAM
Beam Therapeutics Inc
7 May 24
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
7:09am
ARS
2023 FY
BEAM
Beam Therapeutics Inc
19 Apr 24
Annual report to shareholders
4:25pm
DEFA14A
BEAM
Beam Therapeutics Inc
19 Apr 24
Additional proxy soliciting materials
4:20pm
S-3ASR
wxzp5ga
27 Feb 24
Automatic shelf registration
6:10pm
S-8
5ro75l87 b7ozzfaa6ja
27 Feb 24
Registration of securities for employees
7:40am
8-K
3t0mxgooe5 lc3cvd9
27 Feb 24
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
6:43am
8-K
9ci0p8 mro343gz4t7
8 Jan 24
Results of Operations and Financial Condition
6:55am
8-K
ynjskuvkd70awuml3x
14 Dec 23
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
4:05pm
8-K
f0l0wxl38vfrgpir8itr
8 Nov 23
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
7:00am
8-K
mvjjxri egq
31 Oct 23
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
6:44am
8-K
9zbd5dz
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
UPLOAD
wcp2eqhuo9utu8hb7ert
12 Oct 23
Letter from SEC
12:00am
CORRESP
qu5uoirzg8
20 Sep 23
Correspondence with SEC
12:00am
UPLOAD
rvmujrrl
22 Aug 23
Letter from SEC
12:00am
CORRESP
ni5pj4ol
9 Aug 23
Correspondence with SEC
12:00am